Articles tagged with Brain Tumors
The Ralph L. Sacco Scholarships in Brain Health support research into vascular disease's impact on cognitive decline, dementia, and brain health. Researchers Hortense Triniac and Katy Walsh will study protein interactions to reduce stroke risk and investigate cerebral amyloid angiopathy.
Researchers at UT Health San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation by targeting senescent cells with experimental 'senolytic' drugs. This approach shows promise in preventing tumor growth and improving patient survival.
Recent research reveals that avapritinib, a PDGFRA inhibitor, demonstrates potent activity against pediatric high-grade glioma tumors with PDGFRA alterations. Clinical trials in patients showed an initial clinical response and improved survival rates, suggesting the potential for avapritinib as a therapeutic option.
Researchers developed a new diagnostic platform that classifies brain tumors based on the body's cancer-fighting immune response. The approach tailors treatment options to each patient's unique immune profile, offering improved diagnostics and potential for immunotherapies to revolutionize childhood leukemia treatments.
Researchers found that suppressing ZNF638 triggers an antiviral immune response in glioblastoma patients, making them more susceptible to treatment. This finding offers a potential new treatment strategy for the disease, which has remained challenging despite recent advances in immunotherapy.
Researchers identified the prion protein as a key player in the progression of glioblastoma, a type of brain tumor. The study found that blocking the production of this protein using genetic editing reduced the ability of tumor stem cells to proliferate and invade tissues.
Researchers identified PDGFRA as a promising therapeutic target for pediatric high-grade gliomas. Inhibition of the PDGFRA signaling pathway leads to tumor cell death and has shown potential in laboratory and animal models, as well as initial clinical experience with avapritinib therapy.
Researchers found that avapritinib decreases aggressive gliomas in animal models and in an initial cohort of patients with high-grade glioma. The drug targets the PDGFRA gene, which is commonly mutated in this type of cancer.
Researchers developed a new technique to identify aggressive medulloblastoma in children, allowing doctors to tailor treatments and reduce unnecessary side effects. The MYC test can be performed in any pathology lab worldwide, providing faster and more accurate care for young patients with brain tumours.
A new study by Mass General Brigham researchers has found a link between genetic mutations and toxin exposure in firefighters' brain tumors. The study identified a unique pattern of genetic mutations, known as a mutational signature, in many firefighter samples, especially those who had spent more years firefighting.
A new drug formulation called Rhenium Obisbemeda has been shown to significantly extend the median survival and progression-free time of glioblastoma patients, with a median overall survival time of 17 months. The treatment, which uses convection-enhanced delivery, shows promise as a potential cure for this deadly brain tumor.
A new study reveals that radiotherapy has opposite effects on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), with GBM patients living longer after treatment. The study highlights the need for personalized treatment approaches based on genetic and molecular characteristics to improve survival outcomes.
A new study finds that dexamethasone, a commonly prescribed anti-swelling drug, can significantly reduce the body's immune response to brain cancer for weeks after its last dose. This effect is stronger with higher dosages and may impact immunotherapy treatments.
Researchers at Dana-Farber Cancer Institute found that combining navtemadlin with DNA-damaging chemotherapy can increase efficacy in treating glioblastoma. Navtemadlin activates the p53 pathway, killing glioblastoma cells more effectively than other treatments.
Researchers at UCSF have identified unique, cancer-specific proteins created through mistakes in RNA splicing. These antigens could be used to create potent immunotherapies that recognize and attack hard-to-treat tumors. The discovery offers new hope for glioma patients and expands the number of targets available for cancer therapy.
Three University of Arizona Health Sciences faculty members have received career development awards to support their research. Erika Austhof will study the role of weather and ecological drivers in salmonella transmission, while Kristin Huntoon will investigate a drug for treating glioblastomas. Celina Valencia will examine the link be...
A comprehensive review published in Brain Medicine maps out the extensive influence of reproductive hormones on neurological health and disease. The study examines how sex hormones affect a broad spectrum of neurological conditions, including vascular disorders, movement disorders, epilepsy, multiple sclerosis, and Alzheimer's disease.
Researchers identified specific non-frontal brain areas involved in speech intent, which can be used to distinguish between language production and perception. This study is a crucial step towards developing a brain-computer interface to treat patients with Broca's aphasia.
Researchers found a biomarker, RNA Polymerase II (RNAPII), associated with tumor aggressiveness and recurrence in meningioma and breast cancers. The study developed a novel profiling technology, Cleavage Under Targeted Accessible Chromatin (CUTAC), to measure gene transcription activity from DNA, which predicted cancer outcomes.
Scientists at German Cancer Research Center develop innovative method for growing individual brain tumors in lab, mimicking original structure and molecular properties. The IPTO model accurately predicts patient response to chemotherapy and other drugs, offering a valuable tool for personalized medicine.
Researchers found that glioblastoma stem cells are co-localized with myeloid-derived suppressor cells, promoting tumor growth and aggressiveness. The study identified key molecules, such as IL-6 and IL-8, that attract and activate MDSCs, providing new potential therapeutic targets.
The Neuro-Oncology Translational Research Training Program aims to bridge laboratory discoveries and clinical applications in neuro-oncology, targeting glioblastoma and brain metastases. The program provides predoctoral and postdoctoral trainees with cutting-edge lab experience and mentorship across multiple disciplines.
A potential new therapy, CT-179, effectively targets tumor cells and disrupts cancer stem cells, leading to improved treatments and increased survival rates. The novel drug, developed by Curtana Pharmaceuticals, may bring new efficacy to brain tumor therapy.
Researchers have developed a new gene therapy that targets aggressive brain cancer, glioblastoma, with a precise delivery system. The treatment uses a novel virus to deliver a targeting drug to cancer cells, achieving cure rates of up to 90% in mouse models.
Researchers discovered dasatinib inhibits growth of molecular subgroup EPN and activates anti-tumor immune responses. Treatment with dasatinib induced complete regression in 78% of animals, supporting clinical evaluation.
A recent study from Memorial Sloan Kettering Cancer Center sheds new light on the heterogeneity of GBM tumors and the role of cancer stem cells in tumor growth. The research identifies six distinct transcriptional states, each with its own unique gene signature, and provides guidance for future research to develop targeted therapies.
Researchers developed an AI model to detect brain cancer spread in surrounding tissue using MRI scans, showing 85-per-cent accuracy. This non-surgical method offers insights into patients' cancer without aggressive surgery, potentially improving treatment and survival.
Researchers at Uppsala University found that Semliki Forest virus penetrates the central nervous system by entering the cerebrospinal fluid and binding to VLDLR before penetrating deeper into the brain. This finding could be used to develop the virus as an agent for treating brain cancer.
A study suggests targeting endocan, a protein produced by endothelial cells in blood vessels, could slow tumor growth and make glioblastoma more vulnerable to existing treatments. The discovery may lead to new strategies to combat glioblastoma, which has an average lifespan of just 12-15 months.
The study found that COVID-19-related disruptions led to frequent delays in investigations or treatments for children with brain tumors. Caregivers reported feeling traumatized by their experiences, including lack of access to healthcare facilities and social situations, which made it harder to evaluate their concerns.
Scientists at the University of Plymouth are creating a humanised meningioma model to study interactions between immune cells and tumour cells, enabling the development of effective therapies for NF2-related schwannomatosis. The model will be made available worldwide to test new treatments and reduce clinical trial delays.
A phase 2 study conducted by Mayo Clinic found that 56% of participants were alive after 12 months, with a median overall survival of 13.1 months. The treatment, which combines short-course hypofractionated proton beam therapy with advanced imaging techniques, was more effective in patients over 65 with favorable tumor genetics.
Glioblastoma brain tumors synchronize their growth with the daily release of steroid hormones like cortisol, according to new research. Blocking these signals slows tumor growth and disease progression in animal models.
Scientists have created a living cell therapy that can navigate to specific organs using a
A randomized phase 3 trial found that adding temozolomide to radiation therapy improves long-term survival for adult patients with low-grade gliomas. The 10-year survival rate was 70% with combined treatment, compared to 47% with radiation alone.
A new study from UCLA Health Jonsson Comprehensive Cancer Center introduces a combined genetic and functional profiling approach to predict how glioblastoma will respond to therapy. The approach helps identify new ways to target and treat the tumors more effectively, including using an experimental drug called ABBV-155.
Researchers have trained AI models to distinguish brain tumors from healthy tissue using convolutional neural networks and transfer learning. The models achieved an average accuracy of 85.99% at detecting brain cancer, with the ability to generate images showing specific areas in its tumor-positive or negative classification.
The EMA's orphan designation for G2B-002 marks a significant milestone in the fight against pediatric brain tumors. The innovative product leverages Gate2Brain's proprietary technology to enhance drug delivery across the blood-brain barrier, promising enhanced effectiveness and safety for complex cancer treatments.
Researchers developed a new AI-powered diagnostic system, FastGlioma, which reveals invisible cancerous tissue in brain tumor surgery. The technique may delay or prevent recurrence of high-grade tumors and improve patient survival.
Researchers developed an AI-powered model called FastGlioma that can detect residual tumor tissue with high accuracy in 10 seconds. The technology outperformed conventional methods, reducing the risk of missed tumors by nearly 75%. This innovation could change the field of neurosurgery and minimize reliance on radiographic imaging.
Researchers found that non-invasive stereotactic radiosurgery significantly improves tumor control and reduces symptoms such as tinnitus, cranial nerve deterioration, and vestibular dysfunction. Early treatment can prevent tumors from growing over time and spare patients from irreversible problems.
Researchers have developed an immunotherapy that targets glioblastoma by turning its microenvironment against it. The treatment uses CAR T-cells with a blueprint for a molecule that blocks tumor signals, allowing macrophages and microglia to support the attack on cancer cells.
Glioblastoma is a deadly form of brain cancer affecting 500 Swedes annually. Researchers have identified 'foam cells' that aid tumour growth by releasing signal substances and promoting blood vessel formation.
A team of researchers at the University of Toronto has discovered two distinct subtypes of glioblastoma cancer stem cells, each with unique genetic vulnerabilities. By targeting these vulnerabilities, a more effective treatment approach may be developed, improving prognosis for patients with this lethal brain cancer.
A new genomic test using optical genome mapping (OGM) technology will enable faster and more comprehensive diagnosis of brain tumors in children. This innovative approach will help identify novel structural variants that could lead to improved outcomes and new targets for treatment.
A study published in Science Advances has identified key characteristics of multiply recurrent meningiomas (MRMs), a highly aggressive form of brain tumor. Researchers found that MRMs are more numerous, larger and more common in men than women, with increased chromosomal instability and DNA methylation.
Glioblastoma, the most malignant primary brain tumour, has an 18-month median survival rate despite treatment. New research from the University of Ottawa suggests a drug used to slow ALS progression may also suppress glioblastoma's self-renewing cancerous stem cells.
Researchers found Edaravone inhibits growth of brain tumor stem cells and prolongs survival in mice with glioblastoma. The study suggests repurposing Edaravone as a potential treatment for this aggressive brain cancer.
Children who survived childhood brain cancer are more likely to struggle academically, with a greater chance of being held back and performing poorly on state testing. The study's findings highlight the need for better support and resources to help these students succeed.
A recent clinical trial analysis found that patients with truly unmethylated MGMT promoter do not benefit from temozolomide treatment, challenging current treatment protocols. This study aims to transform the treatment landscape for older adults glioblastoma patients by identifying biomarkers for more personalized therapies.
Researchers evaluated the efficacy and safety of using Zika virus for treating CNS tumors, finding that it reduces cell viability, inhibits growth, and decreases Bcl2 expression, potentially enhancing chemotherapy and radiotherapy effects. This ultimately led to significant tumor remission and improved long-term survival through an enh...
A study by Ohio State University researchers found that combining pimozide with CB-839 can effectively suppress glioblastoma growth by blocking lipid production and starvation of tumor cells. This innovative combination may also hold promise for treating other cancers relying on glutamine and lipids.
A study by Osaka Metropolitan University found that ChatGPT's diagnostic performance for brain tumors was comparable to that of neuroradiologists, with an accuracy rate of 73%. The model's performance varied depending on the type of clinical report written, with higher accuracy when using reports from neuroradiologist writers.
A new microscope-integrated OCT system has been developed to identify tumor margins during brain surgery, providing high-resolution images of subsurface anatomy. The system has shown promising results in clinical studies, with the potential to improve outcomes for neurosurgery procedures.
A phase II clinical trial found that radiopharmaceuticals, specifically 177Lu-Dotatate, can extend progression-free survival for patients with refractory meningioma by nearly 80% after six months. The therapy offers a safe and effective treatment option for those with aggressive tumor growth.
Researchers at UNIGE and HUG have developed CAR-T cells capable of targeting malignant gliomas while sparing healthy tissue. The treatment uses a specific marker on tumour cells and appears to be effective in controlling tumour growth without signs of toxicity.
Researchers created an artificial blood vessel model using 3D bioprinting to test new therapies for glioblastoma. This device enables the creation of personalized disease models, potentially improving patient survival rates.
Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.
A new Northwestern Medicine study identifies critical language connector sites in the cerebral cortex that work together to produce language. These sites serve as connectors between subnetworks of people, serving a similar function for language in the brain.
This study presents an advanced U-net segmentation model for brain tumor MRI image segmentation, which incorporates residual grouped convolution and attention mechanisms. The proposed model achieves improved feature extraction ability and segmentation accuracy, resulting in better performance than traditional CNN methods.